Zobrazeno 1 - 10 of 527 pro vyhledávání: '"F. BAERT"'
1
P921 FMT in UC is associated with a decrease in Bacteroides-2 enterotype and response with baseline RNA and microbiota signatures
Autor: S Deleu, C Caenepeel, S Verstockt, J F Vazquez Castellanos, K Arnauts, S Braekeleire, K Machiels, F Baert, F Mana, L Pouillon, P Hindryckx, T Lobaton Ortega, E Louis, D Franchimont, B Verstockt, M Ferrante, J Sabino, S Vieira-Silva, G Falony, J Raes, S Vermeire
Publikováno v: Journal of Crohn's and Colitis. 17:i1029-i1031
Background The efficacy of faecal microbiota transplantation (FMT) in UC has been reported to be donor-, patient- and procedure-dependent (Rees et al., 2022). The RESTORE-UC trial [NCT03110289] aimed to improve the outcome of FMT in patients with act
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8c71fb560ccafd86d76289d5f781d142
https://doi.org/10.1093/ecco-jcc/jjac190.1051
Zobrazit plný text záznamu
2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
3
A37 EFFICACY AND SAFETY OF RISANKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH CROHN’S DISEASE: 52 WEEK RESULTS FROM THE PHASE 3 FORTIFY STUDY
Autor: R Panaccione, M Ferrante, B G Feagan, W Sandborn, J Panes, L Peyrin-Biroulet, J Colombel, S Schreiber, M Dubinsky, F Baert, T Hisamatsu, E Neimark, B Huang, X Liao, A Song, S Berg, W Duan, Y Pang, V Pivorunas, K Kligys, K Wallace, G D’Haens
Publikováno v: Journal of the Canadian Association of Gastroenterology. 5:43-45
Background Risankizumab (RZB), an anti-IL-23 p19 inhibitor, was well-tolerated and superior to placebo (PBO) in inducing clinical remission and endoscopic response in patients (pts) with moderate-to-severe Crohn’s disease (CD) in two phase 3 studie
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6233d4a5337a44338475390972e29cec
https://doi.org/10.1093/jcag/gwab049.036
Zobrazit plný text záznamu
4
P573 Change in fatigue in patients with Ulcerative Colitis or Crohn’s disease initiating vedolizumab or other biologic therapy: Data from Belgian registry patients
Autor: E Louis, P Bossuyt, A Colard, P Caenepeel, F Baert, A Hantson, G Van Gassen, J Zhou, S Vermeire
Publikováno v: Journal of Crohn's and Colitis. 17:i699-i700
Background Fatigue in patients (pts) with ulcerative colitis (UC) and Crohn’s disease (CD) is associated with decreased quality of life. This analysis aimed to describe fatigue evolution and identify factors associated with time to fatigue disappea
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a24654eaf3257f798635fc3fb6543afc
https://doi.org/10.1093/ecco-jcc/jjac190.0703
Zobrazit plný text záznamu
5
P495 Vedolizumab trough concentrations and histological remission in Ulcerative Colitis: Results from the LOVE-UC study
Autor: J Hanzel, F Baert, M Löwenberg, M Ferrante, P Bossuyt, F Hoentjen, D Franchimont, K Palatka, H Peeters, A Mookhoek, G de Hertogh, E Clasquin, S Vermeire, G D'Haens
Publikováno v: Journal of Crohn's and Colitis. 17:i625-i626
Background To date, the association between vedolizumab (VDZ) serum concentrations and histological remission in ulcerative colitis (UC) has not been studied prospectively. VDZ serum concentrations could potentially offer additional guidance for pred
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2f7ec6134e4fc755e2e5681797e711a3
https://doi.org/10.1093/ecco-jcc/jjac190.0625
Zobrazit plný text záznamu
6
P576 Endoscopic healing with vedolizumab in Crohn's disease occurs predominantly in the first 6 months and is independent of serum concentrations: Data from LOVE-CD
Autor: G D'Haens, P Bossuyt, F Baert, T Molnár, E Clasquin, M Lowenberg, N Montazeri, H Peeters, G Lambrecht, S Vermeire
Publikováno v: Journal of Crohn's and Colitis. 17:i704-i705
Background Endoscopic healing is an important treatment goal in Crohn’s disease (CD). Vedolizumab (VDZ) was shown to induce endoscopic healing after 6 months in a significantly greater proportion of pts with early CD than in those with late CD (>2
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7e0e21817b7311b551eda50c5535d882
https://doi.org/10.1093/ecco-jcc/jjac190.0706
Zobrazit plný text záznamu
7
P179 Comparative benefit-risk profile of induction and maintenance therapy with upadacitinib versus placebo in patients with moderately to severely active ulcerative colitis
Autor: I Blumenstein, S Xuan, R Panaccione, F Baert, M Barreiro-de Acosta, B D Ye, J Klaff, R Vladea, G Levy, C T J Holweg, Y Sanchez Gonzalez, M C Dubinsky
Publikováno v: Journal of Crohn's and Colitis. 17:i333-i334
Background Upadacitinib (UPA) demonstrated efficacy and safety as induction and maintenance therapy for ulcerative colitis (UC) in Phase 3 trials U-ACHIEVE (NCT02819635) and U-ACCOMPLISH (NCT03653026). This post-hoc analysis aims to characterise the
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3687a83b9835d7eebd3c1ed419864e88
https://doi.org/10.1093/ecco-jcc/jjac190.0309
Zobrazit plný text záznamu
8
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
9
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
10
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje